Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ: RXRX )

6.935 +0.405 (+6.20%)
Streaming Delayed Price Updated: 2:42 PM EST, Jan 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,481,674
Open 6.740
Bid (Size) 6.930 (52)
Ask (Size) 6.940 (26)
Prev. Close 6.530
Today's Range 6.664 - 7.170
52wk Range 5.600 - 15.74
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025
Via The Motley Fool
AI Drug Discovery Startups: Analysis Of Exscientia’s Acquisition By Recursion
Exscientia is a European player looking to make a difference in the AI-drug discovery market. Like other players, it has an interesting story to tell. After a brief listing on the stock market,... 
Via Talk Markets
Topics Artificial Intelligence Stocks / Equities
Exposures Artificial Intelligence

Performance

YTD
-3.81%
-3.81%
1 Month
-0.79%
-0.79%
3 Month
+2.59%
+2.59%
6 Month
-14.80%
-14.80%
1 Year
-33.83%
-33.83%

More News

Read More
Is Recursion Pharmaceuticals Stock a Buy?
Via The Motley Fool
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce
Via Benzinga
Topics Workforce
Exposures Layoff
AI Drug Discovery Stocks: Recursion Pharmaceuticals Has A Long Road Ahead
Via Talk Markets
Topics Artificial Intelligence Stocks / Equities
Exposures Artificial Intelligence
Is Recursion Pharmaceuticals Stock a Millionaire Maker?
Via The Motley Fool
(RXRX) - Analyzing Recursion Pharmaceuticals's Short Interest
Via Benzinga
Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion to Present at 43rd Annual JP Morgan Healthcare Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
Cathie Wood's Ark Invest Books Profits On Hot AI Stock Palantir, Sells Bitcoin ETF Shares As BTC Starts 2025 On A Positive Note
Via Benzinga
Topics Artificial Intelligence ETFs
Exposures Artificial Intelligence
Nio, Unity Software And Other Big Stocks Moving Higher On Thursday
Via Benzinga
1 Artificial Intelligence (AI) Stock That Could Soar in 2025
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
From Recursion Pharmaceuticals
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
What's Going On With Recursion Pharmaceuticals Stock?
Via Benzinga
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Ulta Beauty Posts Upbeat Results, Joins Asana, Lululemon, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Friday
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
An Investor's Guide to the Artificial Intelligence (AI) Value Chain
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Artificial Intelligence (AI) Redefining Medical Diagnostics Industry That’s Expected to be a $7.2 Billion Market by 2029
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Berkshire Hathaway Isn't the Only Publicly Traded Company That Buys Stocks. These 3 Tech Giants Also Have Stock Portfolios.
Via The Motley Fool
Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
Via Benzinga
NVIDIA Invested in These 2 AI Stocks, Should You?
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.